199 related articles for article (PubMed ID: 31595669)
1. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.
Woodle ES; Tremblay S; Brailey P; Girnita A; Alloway RR; Aronow B; Dasgupta N; Ebstein F; Kloetzel PM; Lee MJ; Kim KB; Singh H; Driscoll JJ
Am J Transplant; 2020 Feb; 20(2):399-410. PubMed ID: 31595669
[TBL] [Abstract][Full Text] [Related]
2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
3. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
[TBL] [Abstract][Full Text] [Related]
4. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.
Li J; Koerner J; Basler M; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2019 Mar; 95(3):611-623. PubMed ID: 30685098
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
[TBL] [Abstract][Full Text] [Related]
6. A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
Tremblay S; Driscoll JJ; Rike-Shields A; Hildeman DA; Alloway RR; Girnita AL; Brailey PA; Woodle ES
Am J Transplant; 2020 Feb; 20(2):411-421. PubMed ID: 31550069
[TBL] [Abstract][Full Text] [Related]
7. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
[TBL] [Abstract][Full Text] [Related]
8. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
Cells; 2021 May; 10(5):. PubMed ID: 34066177
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
Fan Y; You G
Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
[TBL] [Abstract][Full Text] [Related]
11. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
12. Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.
Rossi AP; Tremblay S; Castro-Rojas CM; Burg AA; Roskin KM; Gehman JM; Rike-Shields A; Alloway RR; Brailey P; Allman D; Hildeman DA; Woodle ES
Am J Transplant; 2023 Jun; 23(6):759-775. PubMed ID: 36871629
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
[TBL] [Abstract][Full Text] [Related]
14. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Jenkins TW; Downey-Kopyscinski SL; Fields JL; Rahme GJ; Colley WC; Israel MA; Maksimenko AV; Fiering SN; Kisselev AF
Sci Rep; 2021 May; 11(1):10883. PubMed ID: 34035431
[TBL] [Abstract][Full Text] [Related]
15. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib.
Fraunhoffer NA; Abuelafia AM; Bigonnet M; Gayet O; Roques J; Telle E; Santofimia-Castaño P; Borrello MT; Chuluyan E; Dusetti N; Iovanna J
Clin Cancer Res; 2020 Oct; 26(20):5506-5519. PubMed ID: 32669378
[TBL] [Abstract][Full Text] [Related]
16. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J
Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028
[TBL] [Abstract][Full Text] [Related]
17. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
[TBL] [Abstract][Full Text] [Related]
18. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
20. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]